Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Macrogenics (MGNX) Operating Expenses (2016 - 2025)

Macrogenics (MGNX) has disclosed Operating Expenses for 14 consecutive years, with $53.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 26.14% to $53.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $222.3 million, a 14.66% decrease, with the full-year FY2025 number at $222.3 million, down 14.66% from a year prior.
  • Operating Expenses was $53.3 million for Q4 2025 at Macrogenics, down from $54.2 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $77.7 million in Q1 2022 to a low of $45.9 million in Q3 2023.
  • A 5-year average of $63.2 million and a median of $62.9 million in 2023 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: skyrocketed 31.94% in 2021, then crashed 31.17% in 2023.
  • Macrogenics' Operating Expenses stood at $72.4 million in 2021, then fell by 15.56% to $61.1 million in 2022, then dropped by 1.71% to $60.1 million in 2023, then increased by 20.17% to $72.2 million in 2024, then fell by 26.14% to $53.3 million in 2025.
  • Per Business Quant, the three most recent readings for MGNX's Operating Expenses are $53.3 million (Q4 2025), $54.2 million (Q3 2025), and $59.0 million (Q2 2025).